Search filters
Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI)  5 mg

Renewal reimbursement scheme Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine HCI) 5 mg

17/02/2022

The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg and Xigduo (dapagliflozine & metformine...

Termination TerugBetaalRegeling Tecfidera®

Termination TerugBetaalRegeling Tecfidera®

08/12/2021

As of December 1, 2021, a Personal Contribution for Tecfidera is no longer required. Health insurers will once again fully...

Termination TerugBetaalRegeling Fragmin®2500

Termination TerugBetaalRegeling Fragmin®2500

01/12/2021

From January 1st 2022 onwards, the reimbursement scheme for FRAGMIN (dalteparine)2500 INJVLST 12.500IE/ML WWSP 0,2ML will be...

Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped

Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped

22/09/2021

From September 1st 2021 onwards, Forxiga® (dapagliflozin) 10 mg for the treatment of adults with type 2 diabetes mellitus with a...

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease

Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg - Chronic Kidney Disease

11/08/2021

The health insurer does not yet fully reimburse Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease...

You are currently offline. Some pages or content may fail to load.